Natco Pharma Limited has informed exchanges that its board of directors will meet on March 24, 2026, to consider a proposal for the demerger of its agri business. The company, in a post-market filing dated March 18, said it will evaluate a scheme of arrangement to spin off its Agrosciences Division into its wholly owned subsidiary, Natco Crop Health Sciences Limited, on a going concern basis.
The proposed restructuring is aimed at segregating the agrochemicals business into a separate entity, allowing focused operations and strategic clarity for both segments. The move could potentially help in improving operational efficiencies and enabling better value discovery over the longer term.
The company also stated that the trading window for dealing in its securities will remain closed from March 19 to March 26, 2026 (both days inclusive), in line with SEBI’s insider trading regulations, and will reopen on March 27, 2026.
Since the disclosure was made after market hours, the stock did not react to the development during the trading session. Shares of Natco Pharma ended at ₹957.90 on March 18, up 1.59% for the day.